65 phenotypes from 10 alleles in 13 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Epas1em1(IMPC)Wtsi/Epas1em1(IMPC)Wtsi C57BL/6N-Epas1em1(IMPC)Wtsi/Wtsi	increased total body fat amount	J:211773
Epas1tm1.1Fsl/Epas1+ involves: C57BL/6 * C57BL/6NTac	abnormal heart right ventricle pressure	J:199595
	increased erythrocyte cell number	J:199595
	increased hematocrit	J:199595
	increased hemoglobin content	J:199595
	increased leukocyte cell number	J:199595
	increased lymphocyte cell number	J:199595
	increased monocyte cell number	J:199595
Epas1tm1.1Fsl/Epas1tm1.1Fsl involves: C57BL/6 * C57BL/6NTac	abnormal heart right ventricle pressure	J:199595
	increased circulating erythropoietin level	J:199595
	increased erythrocyte cell number	J:199595
	increased heart weight	J:199595
	increased hematocrit	J:199595
	increased hemoglobin content	J:199595
	increased leukocyte cell number	J:199595
	increased monocyte cell number	J:199595
	increased pulmonary respiratory rate	J:199595
	increased spleen weight	J:199595
	lethality, incomplete penetrance	J:199595
	pulmonary artery hypoplasia	J:199595
	thick ventricular wall	J:199595
Epas1tm1.1Mcs/Epas1+ involves: 129X1/SvJ * C57BL/6 * CBA	abnormal physiological response to hypoxia	J:302384
	abnormal type I cell of carotid body physiology	J:302384
Epas1tm1.1Mcs/Epas1tm1.1Mcs involves: 129X1/SvJ * FVB/N	prenatal lethality, complete penetrance	J:119731
Epas1tm1b(EUCOMM)Hmgu/Epas1+ C57BL/6N-Epas1tm1b(EUCOMM)Hmgu/H	abnormal heart morphology	J:211773
	decreased hemoglobin content	J:211773
Epas1tm1b(EUCOMM)Hmgu/Epas1tm1b(EUCOMM)Hmgu C57BL/6N-Epas1tm1b(EUCOMM)Hmgu/H	preweaning lethality, complete penetrance	J:211773
Epas1tm1Fong/Epas1tm1Fong involves: 129S1/Sv * 129X1/SvJ	abnormal angiogenesis	J:63415
	abnormal vitelline vasculature morphology	J:63415
	embryonic lethality during organogenesis, complete penetrance	J:63415
	hemorrhage	J:63415
Epas1tm1Fong/Epas1tm1Fong involves: 129S1/Sv * 129X1/SvJ * ICR	abnormal vitelline vasculature morphology	J:63415
	decreased birth body size	J:63415
	embryonic lethality during organogenesis, incomplete penetrance	J:63415
	hemorrhage	J:63415
	postnatal lethality, incomplete penetrance	J:63415
Epas1tm1Mcs/Epas1tm1.1Mcs Ndor1Tg(UBC-cre/ERT2)1Ejb/0 involves: 129X1/SvJ * FVB/N	abnormal hematopoietic system physiology	J:119731
	abnormal proerythroblast morphology	J:119731
	anemia	J:119731
	decreased erythrocyte cell number	J:119731
	decreased hematocrit	J:119731
	decreased hemoglobin content	J:119731
	enlarged spleen	J:119731
	reticulocytopenia	J:119731
Epas1tm1Mcs/Epas1tm1.1Mcs Tg(CAG-cre/Esr1*)5Amc/0 involves: 129X1/SvJ * C57BL/6 * CBA	abnormal physiological response to hypoxia	J:302384
	abnormal type I cell of carotid body physiology	J:302384
	anemia	J:302384
	normal cardiovascular system phenotype	J:302384
	decreased hematocrit	J:302384
	heart left ventricle hypertrophy	J:302384
Epas1tm1Mcs/Epas1tm1Mcs Tg(CD68-icre)1Bwlx/0 involves: 129X1/SvJ * C57BL/6	normal mortality/aging	J:194598
Epas1tm1Mcs/Epas1tm1Mcs Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 involves: 129S1/Sv * 129X1/SvJ * CD-1	decreased erythroid progenitor cell number	J:186085
Epas1tm1Pec/Epas1+ involves: 129/Sv * Swiss	abnormal cardiovascular system physiology	J:83549
	decreased susceptibility to injury	J:83549
Epas1tm1Pec/Epas1tm1Pec involves: 129/Sv * Swiss	abnormal alveolar lamellar body morphology	J:77480
	abnormal angiogenesis	J:77480
	abnormal lung development	J:77480
	abnormal lung vasculature morphology	J:77480
	abnormal pulmonary alveolus epithelial cell morphology	J:77480
	abnormal surfactant secretion	J:77480
	atelectasis	J:77480
	cyanosis	J:77480
	decreased type II pneumocyte number	J:77480
	embryonic lethality during organogenesis, incomplete penetrance	J:77480
	neonatal lethality, complete penetrance	J:77480, J:83549
	prenatal lethality, incomplete penetrance	J:83549
	respiratory distress	J:77480
	respiratory failure	J:77480
	thick pulmonary interalveolar septum	J:77480
Epas1tm1Rus/Epas1tm1Rus either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)	congestive heart failure	J:50964
	decreased circulating noradrenaline level	J:50964
	decreased heart rate	J:50964
	embryonic lethality during organogenesis, incomplete penetrance	J:50964
	heart vascular congestion	J:50964
	lethality throughout fetal growth and development, complete penetrance	J:50964
	liver vascular congestion	J:50964
	visceral vascular congestion	J:50964
Epas1tm1Yfk/Epas1tm1Yfk involves: 129P2/OlaHsd * C57BL/6J	abnormal eye electrophysiology	J:82257
	abnormal physiological neovascularization	J:82257
	abnormal retina inner nuclear layer morphology	J:82257
Epas1tm1Yms/Epas1tm1Yms Tg(Vil1-cre)20Syr/0 B6.Cg-Epas1tm1Yms Tg(Vil1-cre)20Syr	decreased circulating iron level	J:189504
	decreased erythrocyte cell number	J:189504
	decreased hematocrit	J:189504
	decreased hemoglobin content	J:189504